PharmacoEconomics

Acknowledgement
pp. 1167-1169(3)
Author: Adis International Limited

Valuing Prevention Through Economic Evaluation: Some Considerations Regarding the Choice of Discount Model for Health Effects with Focus on Infectious Diseases
pp. 1171-1179(9)
Authors: Jasper M. Bos; Philippe Beutels; Lieven Annemans; Maarten J. Postma

Economic Costs to Business of the HIV/AIDS Epidemic
pp. 1181-1194(14)
Authors: Gordon G. Liu; Jeff J. Guo; Scott R. Smith

Discrete Choice Experiment to Derive Willingness To Pay for Methyl Aminolevulinate Photodynamic Therapy Versus Simple Excision Surgery in Basal Cell Carcinoma
pp. 1195-1208(14)
Authors: Adele Weston; Patrick FitzGerald

The Effect of Cost Construction Based on Either DRG or ICD-9 Codes or Risk Group Stratification on the Resulting Cost-Effectiveness Ratios
pp. 1209-1216(8)
Authors: Elinor C.G. Chumney; Andrea K. Biddle; Kit N. Simpson; Morris Weinberger; Kathryn M. Magruder; William N. Zelman

The Economic Implications of Non-Adherence after Renal Transplantation
pp. 1217-1234(18)
Authors: Irina Cleemput; Katrien Kesteloot; Yves Vanrenterghem; Sabina De Geest